Aurobindo Pharma’s shares went down by 7 per cent to hit an over last two years below Rs 457.20 on the Bombay Stock Exchange (BSE) after the company reported in the second quarter of FY23. On a consolidated basis, the net profit in the second quarter of FY23 came 41 per cent lower on a YoY basis at Rs 409 crore.

• RBI Defends Currency Moves to Protect Economy
• Trump 2.0: Drilling, Climate Rollbacks, and Global Energy Concerns
• Nvidia’s AI Chip Demand Soars, But Slowing Sales Growth Worries Investors
• Karnataka CM Siddaramaiah Meets UK Envoy, Highlights Progressive Industry Policy
• What is Fair Market Value (FMV): Formula, Taxation & Example

Revenue from operations fell by 3.4 per cent year on year to Rs 5,739 crore in the second quarter of FY23 compared with Rs 5,942 crore in 2022. EBITDA margin decreased from 20 per cent to 14.6 per cent.

The company said the second quarter performance was subdued mainly due to the macro-environment factors and higher competitive intensity for some products in the US.